- Home>
- Specialty Care>
- Oncology and Hematology>
- About>
- About Our Editorial Board
About the Journal Watch Oncology and Hematology Editorial Board
William J. Gradishar, MD, Editor-in-Chief
Dr. Gradishar is Professor of Medicine in the Feinberg School of Medicine at Northwestern University and a member of the Robert H. Lurie Comprehensive Cancer Center. He serves as Director of Maggie Daley Center for Women�s Cancer Care at Northwestern University and Northwestern Memorial Hospital. He has served as Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception. He was most recently honored as the Betsy Bramsen Professor of Breast Cancer (2011). Dr. Gradishar has been Editor-in-Chief for Journal Watch Oncology and Hematology since 2006.
Robert Dreicer, MD, MS, FACP, Associate Editor
Dr. Dreicer is the Chair of the Department of Solid Tumor Oncology at Cleveland Clinic in Cleveland, Ohio. He received his Medical Degree and Master of Science from the University of Texas�Houston. He completed internal medicine residency training at Indiana University and a medical oncology fellowship at the University of Wisconsin. He is a fellow of the American College of Physicians. Dr. Dreicer is an academic clinical investigator in the area of urologic oncology. He chairs the bladder subcommittee in the Eastern Cooperative Oncology Group and is a member of the American Board of Internal Medicine, Medical Oncology Subspecialty Board. Dr. Dreicer has been writing for Journal Watch Oncology and Hematology since 2006.
Ramaswamy Govindan, MD, Associate Editor
Dr. Govindan is the Co-Director of the Section of Medical Oncology at the Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis.
David Green, MD, PhD, Associate Editor
Dr. Green is Professor of Medicine Emeritus in the Division of Hematology/Oncology, Department of Medicine, at the Feinberg School of Medicine of Northwestern University. His clinical and research interests are in the area of bleeding and thrombosis. He has authored more than 300 journal articles and textbook chapters and has edited six books. He serves on the board of the American Thrombosis and Hemostasis Network. He is a member of the American Society of Hematology, a fellow of the American Heart Association, and a Master of the American College of Physicians. Dr. Green has been writing for Journal Watch Oncology and Hematology since 2006.
David H. Ilson, MD, PhD, Associate Editor
Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an MD, PhD combined degree program at New York University and received a Master�s degree and PhD in Basic Science and an MD from New York University. He completed his internship and residency in internal medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in medical oncology and hematology, including a third-year fellowship as the Brian Piccolo research fellow. He joined the staff at MSKCC in 1992, becoming a member of the GI Oncology Service in the Department of Medicine. He was a recipient of an American Cancer Society Career Development Award. Dr. Ilson is now an attending physician and member at Memorial Hospital and is professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. He is a nationally recognized authority in the treatment of gastrointestinal cancer. His research has focused on the study of new agents in advanced esophageal cancer and on the evaluation of novel agents in combined modality therapy programs in locally advanced disease. He sits on the GI committees of Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG) as well as the Upper GI Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN). He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee. He currently chairs or co-chairs several national clinical trials in esophageal cancer. Dr. Ilson has been writing for Journal Watch Oncology and Hematology since 2006.
Henry Mark Kuerer, MD, PhD, FACS, Associate Editor
Dr. Kuerer, MD, PhD, FACS, is the training Program Director of Breast Surgical Oncology and a tenured Professor of Surgery at The University of Texas M. D. Anderson Cancer Center. Dr. Kuerer is a recognized cancer surgeon and researcher who specializes in the multidisciplinary surgical care of patients with breast cancer. Dr. Kuerer is Chair of the American College of Surgeons Oncology Group Education Committee and a member of its Executive Committee. He serves as Principal Investigator for the National Surgical Adjuvant Breast and Bowel Project at M. D. Anderson, is an Editor of several clinical journals, and is a member of the American Society of Breast Surgeons and the Society of Surgical Oncology. He is a regularly invited speaker at academic, national, and international meetings and has authored or coauthored more than 300 peer-reviewed scientific reports, editorials, and textbook chapters. Dr. Kuerer is Editor-in-Chief of the new definitive McGraw-Hill textbook, Breast Surgical Oncology. Originally from New Jersey, he attended Rutgers College and received his MD and PhD in Molecular Immunology at the State University of New York Health Science Center in Brooklyn, trained in general surgery at the Mount Sinai School of Medicine in New York City, and completed his fellowship training at M. D. Anderson. Dr. Ilson has been writing for Journal Watch Oncology and Hematology since 2006.
Barbara A. Murphy, MD, Associate Editor
Barbara A. Murphy, MD, is Associate Professor of Medicine in the Division of Hematology/Oncology and Director of the Pain and Symptom Management Program at Vanderbilt University, Nashville, TN. Dr. Murphy has been writing for Journal Watch Oncology and Hematology since 2007.
Michael E. Williams, MD, Associate Editor
Dr. Williams is the Byrd S. Leavell Professor of Medicine, Professor of Pathology, and Chief, Hematologic Malignancies Section, Hematology/Oncology Division, University of Virginia School of Medicine, Charlottesville. Dr. Williams received his MD from the University of Cincinnati College of Medicine and a Master of Science in Microbiology from the Harvard School of Public Health. He completed his Medicine residency, Chief Residency, and Fellowship in Hematology/Oncology at the University of Virginia Health System in Charlottesville, where he joined the faculty in 1986. He currently serves as Chief of the Hematologic Malignancies Section in the UVA Cancer Center and the Hematology/Oncology Division. His research interests are in the pathogenesis and immunotherapy of non-Hodgkin lymphoma and chronic lymphocytic leukemia, and in new therapeutic approaches for hematologic malignancies. Dr. Williams serves on the Scientific Advisory Board of the Lymphoma Research Foundation, chaired the Executive Committee for the LRF Mantle Cell Lymphoma Consortium 2005�2010, and is a member of the Scientific Advisory Board of the European Mantle Cell Lymphoma Network. He is a member of the Hematology Subspecialty Board of the American Board of Internal Medicine and participates regularly in regional and national programs devoted to education and research in lymphoma and hematologic malignancies. Dr. Williams has been writing for Journal Watch Oncology and Hematology since 2006.
EDITORS WHO HAVE LEFT THE BOARD SINCE JANUARY 2007
Lin-Chi Chen, MD, PhD, Associate Editor
Dr. Chen is a medical oncologist specializing in lung cancer at the Nevada Cancer Institute. She was an associate editor for Journal Watch Oncology and Hematology from 2008 to 2011.
Manuel Hidalgo, MD, PhD, Associate Editor 2006-2008
Dr. Hidalgo is an Associate Professor of Oncology and Co-Director of the Drug Development Program at Johns Hopkins University School of Medicine. He received his medical degree from the University Navarra Medical School in Pamplona, Spain, and his doctorate degree from the University of Autonoma in Madrid, Spain. In 1997, he began his career as a clinical research fellow at the Cancer Therapy and Research Center in San Antonio, Texas, where he participated in the EORTC/NCI Exchange Fellowship and AACR Young Investigator Fellowship in Clinical Research. He worked as both an Assistant Professor of Medicine at the University of Texas Health Science Center and as a clinical investigator at the Cancer Therapy and Research Center. He received an ASCO Career Development Award in 2001. Dr. Hidalgo wrote for Journal Watch Oncology and Hematology from its inception in 2006 through 2008.
Mark A. Socinski, MD, Associate Editor 2006�2007
Dr. Socinski serves as the Director of the Multidisciplinary Thoracic Oncology Program at the University of North Carolina and Lineberger Comprehensive Cancer Center (LCCC). His primary research involves clinical trials in both non-small cell (NSCLC) as well as small cell lung cancer (SCLC). He is the Principal Investigator for several national and investigator-initiated LCCC trials on the optimal chemotherapeutic approach to advanced, metastatic NSCLC. Dr. Socinski serves as chair of a national trial of novel chemotherapeutic approaches in stage I and II NSCLC as pre-operative therapy. He is currently involved with the American College of Chest Physicians Lung Cancer Guidelines Committee and serves on the Advisory Board of Lungcancer.org. He wrote for Journal Watch Oncology and Hematology from its inception in 2006 through 2007.
